

Acute Lung Injury Therapeutic and Drug Pipeline Review H2

Acute Lung Injury Therapeutic Pipeline Market Review, H2 2017

PUNE, INDIA, January 11, 2017
/EINPresswire.com/ -- [Acute Lung Injury](#)
- Pipeline Review, H2 2016

GET SAMPLE REPORT @
<https://www.wiseguyreports.com/sample-request/867068-acute-lung-injury-pipeline-review-h2-2016>

Summary

Acute lung injury (ALI) is a common condition that is characterized by acute severe hypoxia that is not due to left atrial hypertension. ALI is most often seen as part of a systemic inflammatory process, particularly systemic sepsis, where the lung manifestations parallel those of other tissues. Causes of ALI include sepsis, burns, radiation, inhalation of noxious fumes and fat embolism. Symptoms include severe shortness of breath, low blood pressure, confusion and extreme tiredness

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Acute Lung Injury – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Lung Injury (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Lung Injury (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Lung Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 19 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 3 molecules, respectively.

Acute Lung Injury (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lung Injury (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Acute Lung Injury (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Lung Injury (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Lung Injury (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lung Injury (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Lung Injury (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Lung Injury (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Acute Lung Injury Overview 10

Therapeutics Development 11

Pipeline Products for Acute Lung Injury - Overview 11

Pipeline Products for Acute Lung Injury - Comparative Analysis 12

Acute Lung Injury - Therapeutics under Development by Companies 13

Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes 15

Acute Lung Injury - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

...Continued

ACCESS REPORT @ <https://www.wiseguyreports.com/reports/867068-acute-lung-injury-pipeline->

[review-h2-2016](#)

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.